TY - JOUR
T1 - Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue
T2 - A European Mantle Cell Lymphoma Network Study
AU - Morello, Lucia
AU - Rattotti, Sara
AU - Giordano, Laura
AU - Jerkeman, Mats
AU - van Meerten, Tom
AU - Krawczyk, Katarzyna
AU - Moita, Filipa
AU - Marino, Dario
AU - Ferrero, Simone
AU - Szymczyk, Michał
AU - Aurer, Igor
AU - El-Galaly, Tarec Christoffer
AU - Di Rocco, Alice
AU - Visco, Carlo
AU - Carli, Giuseppe
AU - Defrancesco, Irene
AU - Carlo-Stella, Carmelo
AU - Dreyling, Martin
AU - Santoro, Armando
AU - Arcaini, Luca
PY - 2020/2
Y1 - 2020/2
N2 - While classical nodal mantle cell lymphoma (cMCL) is often associated with involvement of multiple extranodal sites, isolated extranodal disease (ED) at the time of diagnosis is a rare event; data on the outcome of these forms are lacking. On behalf of the European MCL Network, we conducted a retrospective analysis on the clinical characteristics and outcomes of MCL presenting with isolated or predominant ED (MALT MCL). We collected data on 127 patients with MALT MCL diagnosed from 1998 to 2015: 78 patients (61%) were male with a median age of 65 years. The involved sites include: upper airways + Waldeyer ring (40; 32%), gastrointestinal tract (32; 25%), ocular adnexa (17; 13%), oral cavity and salivary glands (17; 13%) and others (13; 1%); 7 patients showed multiple extranodal sites. The median follow-up was 80 months (range: 6-182), 5-year progression-free survival (PFS) was 45% (95% CI: 35-54) and 5-year overall survival (OS) was 71% (95% CI: 62-79). In an explorative setting, we compared MALT MCL with a group of 128 cMCL patients: MALT MCL patients showed a significantly longer PFS and OS compared with nodal cMCL; with a median PFS of 4.5 years vs 2.8 years (p = 0.001) and median OS of 9.8 years vs 6.9 years (p = 0.018), respectively. Patients with MALT MCL at diagnosis showed a more favorable prognosis and indolent course than classical nodal type. This clinical variant of MCL should be acknowledged to avoid possible over-treatment.
AB - While classical nodal mantle cell lymphoma (cMCL) is often associated with involvement of multiple extranodal sites, isolated extranodal disease (ED) at the time of diagnosis is a rare event; data on the outcome of these forms are lacking. On behalf of the European MCL Network, we conducted a retrospective analysis on the clinical characteristics and outcomes of MCL presenting with isolated or predominant ED (MALT MCL). We collected data on 127 patients with MALT MCL diagnosed from 1998 to 2015: 78 patients (61%) were male with a median age of 65 years. The involved sites include: upper airways + Waldeyer ring (40; 32%), gastrointestinal tract (32; 25%), ocular adnexa (17; 13%), oral cavity and salivary glands (17; 13%) and others (13; 1%); 7 patients showed multiple extranodal sites. The median follow-up was 80 months (range: 6-182), 5-year progression-free survival (PFS) was 45% (95% CI: 35-54) and 5-year overall survival (OS) was 71% (95% CI: 62-79). In an explorative setting, we compared MALT MCL with a group of 128 cMCL patients: MALT MCL patients showed a significantly longer PFS and OS compared with nodal cMCL; with a median PFS of 4.5 years vs 2.8 years (p = 0.001) and median OS of 9.8 years vs 6.9 years (p = 0.018), respectively. Patients with MALT MCL at diagnosis showed a more favorable prognosis and indolent course than classical nodal type. This clinical variant of MCL should be acknowledged to avoid possible over-treatment.
U2 - 10.1097/HS9.0000000000000302
DO - 10.1097/HS9.0000000000000302
M3 - Journal article
C2 - 32072136
SN - 2572-9241
VL - 4
SP - 1
EP - 6
JO - HemaSphere
JF - HemaSphere
IS - 1
M1 - e302
ER -